Does TASIGNA Cause Second primary malignancy? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Second primary malignancy have been filed in association with TASIGNA. This represents 2.1% of all adverse event reports for TASIGNA.
16
Reports of Second primary malignancy with TASIGNA
2.1%
of all TASIGNA reports
2
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From TASIGNA?
Of the 16 reports, 2 (12.5%) resulted in death, 4 (25.0%) required hospitalization, and 1 (6.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TASIGNA. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does TASIGNA Cause?
Death (76)
Fatigue (67)
Rash (53)
Nausea (42)
Dyspnoea (37)
Headache (31)
Chronic myeloid leukaemia (30)
Malignant neoplasm progression (28)
Anaemia (27)
Electrocardiogram qt prolonged (27)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TASIGNA Alternatives Have Lower Second primary malignancy Risk?
TASIGNA vs TASIMELTEON
TASIGNA vs TAVABOROLE
TASIGNA vs TAXOL
TASIGNA vs TAXOTERE
TASIGNA vs TAZAROTENE